Last updated: February 14, 2026
Overview of NDA 51672-4043
NDA 51672-4043 refers to Nintedanib, marketed under the brand name Ofev. It is approved for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and other fibrotic interstitial lung diseases.
Market Size and Growth Drivers
- Global IPF Market: Valued approximately USD 2.2 billion in 2022; expected to grow at compound annual growth rate (CAGR) of 7.2% through 2030.
- Key Indications for Nintedanib:
- IPF
- SSc-ILD
- Other fibrotic diseases
- Market Penetration:
- Nintedanib has a dominant position in IPF (over 75% market share in approved regions).
- Growth in SSc-ILD indications expands the addressable market.
Competitive Landscape
- Primary competitor: Pirfenidone (Esbriet).
- Market shares: Nintedanib holds approximately 55-60% with Esbriet at 40-45% in the IPF segment (2022 data).
- Emerging treatments target additional fibrotic indications, expanding market opportunities.
Pricing and Reimbursement Landscape
- United States:
- List price: Approximately USD 9,682 per month (~USD 116,000 annually) per patient.
- Reimbursement varies; private insurers and Medicare Part D provide coverage, often with negotiated discounts.
- Europe:
- Prices range from EUR 8,000 to EUR 12,000 annually, depending on country and healthcare system.
- Japan:
- Regulations and reimbursement set prices around JPY 1.2 million (~USD 10,900) annually.
- Impact of Biosimilars and Generics:
- Currently, no biosimilars approved; price erosion expected as patents expire (initial patent expiration estimated 2027).
Patent and Regulatory Status
- Patent protections for of Nintedanib extend until 2027–2028 in key markets.
- A pipeline of new indications under clinical trial phases could extend revenue streams beyond patent expiration.
Financial Projections
| Year |
Estimated Revenue (USD Billions) |
Assumptions |
| 2023 |
2.45 |
Continued market share, moderate price increases |
| 2025 |
2.70 |
Expand to additional fibrotic diseases, new indications |
| 2030 |
3.20 |
Market expansion, increased adoption, biosimilar entries expected post-2027 |
Price Projections to 2030
- Pricing trend: Slight decrease in list prices (~2-5%) annually due to biosimilar competition anticipated post-2027.
- Reimbursement adjustments:
- US: Discounts and rebates will likely account for 20-30% reduction from list price.
- Europe and Japan: Similar discounting trends; price erosion expected overall.
- Net Price Estimation:
- US: Approximately USD 8,500–USD 9,000 per month (~USD 102,000–USD 108,000 annually) by 2030.
- EU/Japan: Corresponding adjusted prices range from EUR 7,000–EUR 10,000 annually.
Risks and Opportunities
- Regulatory delays or restrictions could limit revenue growth.
- Post-patent biosimilar entry could reduce pricing power.
- New indications and combination therapies offer growth opportunities.
- Manufacturing costs are expected to decline marginally with increased scale, supporting margin preservation.
Key Takeaways
- The global Nintedanib market is projected to grow at a CAGR of roughly 7% through 2030.
- Price declines of 2-5% annually are expected due to biosimilar competition beginning around 2027.
- US prices could average USD 8,500–USD 9,000 monthly in 2030, with similar trends in Europe and Japan.
- Revenue growth hinges on expanding indications, market penetration, and regulatory factors.
- Patent expirations are critical to near-term pricing and market dynamics.
Frequently Asked Questions
1. When are the patent protections for Nintedanib expected to expire?
Patents in major markets are set to expire between 2027 and 2028, opening the pathway for biosimilar competition.
2. What is the current market share of Nintedanib in IPF treatment?
It holds over 75% of the market share in regions where it is approved, competing mainly with Pirfenidone.
3. How are prices expected to change post-patent expiration?
Prices are expected to decrease by 20-30%, influenced by biosimilar entry, reimbursement negotiations, and market competition.
4. What growth opportunities exist beyond IPF?
Clinical development of Nintedanib for additional fibrotic diseases and innovative combination therapies present future expansion pathways.
5. What are the primary risks affecting Nintedanib's market projection?
Regulatory restrictions, biosimilar price erosion, delayed approvals for new indications, and unfavorable reimbursement policies pose risks.
References
[1] MarketsandMarkets. "Interstitial Lung Disease Therapeutics Market," 2022.
[2] IQVIA. "Global Biopharmaceutical Market Trends," 2022.
[3] company filings and European Medicines Agency (EMA) approvals.
[4] Evaluate Pharma. "Forecasts and Price Trends," 2022.
[5] Japanese Ministry of Health, Labour and Welfare. Reimbursement data, 2022.
